Bladder Cancer Advocacy Network's Seattle Walk to End Bladder Cancer was a huge success - JJ Zhang, MD
Petros Grivas VirginiaMasonUrology Bladder Cancer Advocacy Network Jonathan L Wright Sarah P. Psutka MD MS Dimitra Bakaloudi MD, MS
Betsy Koehne IBCG Dimitrios (Dimitri) Makrakis
oncodaily.com/70522.html

#Cancer #Oncology #OncoDaily

#ASCO24 ASCO Educational session on EGFR Mutant #NSCLC EGFR Resisters
Add to agenda, download the PDF in the educational book and catch live at the Annual Meeting! #LCSM
Jordi Remon Xiuning Le MD PhD Lizza Hendriks Stephanie Saw

#1 T-6 #ASCO 24 ! Have been watching out for all the #curated lists on #lcsm #bcsm #mmsm #melsm #blcsm #kcsm and #community oncology! Ft. Aakash Desai, MD, MPH Paolo Tarantino Dipesh Uprety MD FACP Mike Thompson, MD, PhD, FASCO Tarek Haykal, MD, MHS Toni Choueiri, MD
#ASCO Featured Voices, add more if you find them!
Omar Abdihamid Oncologist @Garissa Cancer Center,

T-6 for #ASCO24 !

📝 Here are some key takeaways #ASCOTips

1️⃣ Plan Ahead: 🕰️Study the program, 🌐adjust for time zones, 🏨book lodgings early, and pack comfortable shoes👟 & snacks🥪. Download ASCO meeting app 📲

2️⃣ Conference Strategy: 🎯Prioritize sessions, add to 'My

Thanks Nathan A. Pennell MD, PhD, FASCO ASCO dream team!

Ab#5055 ASCO #ASCO24 by Edmond Kwan👉tinyurl.com/3jusvkmj👉In TheraP ph2 trial of Lu-177 vs. cabazitaxel in mCRPC #prostatecancer 👉 Higher ctDNA fraction associated with⬇️PSMA exp, ⬆️ FDG uptake, & ⬇️response to Lu-177👇 #AlexanderWyatt OncoAlert UroToday.com PCF Science

American Society of Clinical Oncology abstracts on phase EV-202 results have just been released -
Niklas Klümper
ASCO IEO_HölzelLab
oncodaily.com/insight/71401.…… #ASCO24

#Cancer #ClinicalTrial #UrothelialCarcinoma #OncoDaily #Oncology

Join us for a fun educational session on June 1 to review ADCs in #bladdercancer with Tian Zhang, MD, MHS & #EvanYu

Bladder Cancer Advocacy Network Omar Mian Omar Alhalabi, MD Vadim Koshkin MD Karine Tawagi MD Priyanka Chablani, MD, MS Bárbara Melão Vinay Mathew Thomas Arnab Basu Dimitra Bakaloudi MD, MS Fuat Bicer MD, PhD Rohit Jain, MD Pedro C Barata, MD MSc FACP

Welcoming wonderful teams with amazing colleagues/friends to compete for Uromigos cup! Our team is ready to defend our title! Sumanta K. Pal, MD, FASCO Tanya Dorff

Neeraj Agarwal, MD, FASCO Petros Grivas Clinical Cancer Research Sumanta K. Pal, MD, FASCO Shilpa Gupta Thomas Flaig Tom Powles Amanda Nizam, MD Vadim Koshkin MD Enrique Grande Congrats PGrivasMDPhD and team! The detailed characterization of Debio1347, including transcriptomic data, is highly commendable.

Congrats to Petros Grivas and team for this Clinical Cancer Research paper characterizing a novel FGFR inhibitor. Groundbreaking work indeed. Sumanta K. Pal, MD, FASCO Shilpa Gupta Thomas Flaig Tom Powles Amanda Nizam, MD Vadim Koshkin MD Enrique Grande

Huge congrats Petros Grivas and team on this translational work with novel FGFR inhibitor #Debio1347 👇👇

The network that continues to amaze !
OncoAlert with Gil Morgan, MD !

TOP 10 abstract list regarding kidney and bladder cancer by the OncoAlert GU team for #ASCO24 👇

Emre Yekedüz Dra. María Natalia Gandur Quiroga Gil Morgan, MD 🌐

It's not too late to join us at the most significant gathering of oncology professionals worldwide.

Register for #ASCO24 today! brnw.ch/21wK8is

Dear Colleagues,
The OncoAlert 🚨Network Presents OUR Picks of
TOP 🔟Abstracts to be Presented at #ASCO24 for #KidneyCancer & #BladderCancer

This List Curated by:
#OncoAlertAF Leads : Emre Yekedüz 🇺🇸 Dra. María Natalia Gandur Quiroga 🇦🇷 Gil Morgan, MD 🇺🇸
Distinguished faculty Toni Choueiri, MD 🇺🇸

Thanks Sumanta K. Pal, MD, FASCO for highlighting our work with #KeithFlaherty & many stellar colleagues for a basket trial across FGFR-fused cancers!Trying to learn from all trials dissecting into biology! Razelle Kurzrock, MD Andres Cervantes Josep Tabernero Nataliya Uboha Elena Garralda OncoAlert

Sharing my thoughts with GU Oncology Now on the newly opened MoonRISe-1 trial evaluatingTAR-210 for Intermediate-Risk NMIBC and the future of targeted therapy in #NMIBC Johnson & Johnson Innovation Bladder Cancer Advocacy Network IBCG

guoncologynow.com//post/moonrise…

Ab#5010 ASCO #ASCO24 by Michael Morris👉tinyurl.com/5n6eh44e👉Ph1 study of Actinium-225-labeled antibody (JNJ-6420) targeting human kallikrein 2 #prostatecancer 👉1-2 doses elicited encouraging PSA & radiographic responses👇 #OSartor GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com PCF Science

Ab#4506 ASCO #ASCO24 by Laurence Albiges Brian Rini, MD 👉tinyurl.com/mtdxdx2u👉 Ph2 IMmotion010 trial of adj atezolizumab vs. placebo #kidneycancer 👉⬆️baseline serum KIM-1 levels ➡️poorer prognosis & ⬆ outcomes with atezolizumab vs. placebo 👇 OncoAlert UroToday.com Uromigos